This topic is lockedNMN
* David Sinclair's NMN safety trial complete but not published.
NR
* Chromadex hasn't had its 140 person NR trial published yet. At the site aboutnad.com, the link to the study is dead.
* Copenhagen study completed in 2015, not published.
*Iowa St. U., Effects of Nicotinamide Riboside on Metabolism and Vascular Function, 500 mg/day of NR for 7 days, 18-35 year olds and 60- 75 year olds; completed in December 2018.
* Chromadex, Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults, 300 mg NR / 1000 mg of NR for 8 weeks, 40 people with age = 55+; completed in March 2019.
* National Heart, Lung, and Blood Institute (NHLBI) on the Effect of Nicotinamide Riboside on Immunity, 1,000 mg of NR, 18 to 39 year olds; completed in March 2019.
* Mayo Clinic / U of MN, Use of 31P MRS to Assess Brain NAD+ in Healthy Collegiate Athletes, 750 mg of NR, 12 weeks, age 18+, completed in June 2019.
* U of Washington, Nicotinamide Riboside in Systolic Heart Failure, ramp up to 1,000 mg of NR by week 4 of 12 week study, ejection fraction (EF) >40; completed in June 2019.
-------------------------------------------
So.... Chromadex might announce its 140 person study results this yea then maybe results on cognitive function will be released next year. I wonder how Charles Brenner already knows the results of a heart failure trial, which seems to be the one at the U of Washington, but that won't be for another ten months. If the results are positive, wouldn't there be a moral obligation for the U of Washington to let the millions of people with heart failure know about the results?
